Table 2 Treatment, complications, and outcomes in patients hospitalized with COVID-19 (prisoners vs. non-prisoners).
Prisoners (N = 108) | Non-prisoners (N = 598) | p value | |
|---|---|---|---|
Therapeutics and medications | |||
Highest O2 requirement | |||
Ambient air | 16 (14.8%) | 150 (25.1%) | 0.02 |
Nasal cannula | 23 (21.3%) | 271 (45.3%) | < 0.001 |
High-flow nasal cannula | 38 (35.2%) | 78 (13.0%) | < 0.001 |
NIVMa | 4 (3.7%) | 7 (1.2%) | 0.05 |
IMVa | 27 (25.0%) | 92 (15.4%) | 0.01 |
Antibiotics | 55 (50.9%) | 271 (45.3%) | 0.28 |
Corticosteroids | 95 (88.0%) | 466 (78.0%) | 0.02 |
Anticoagulation | 103 (95.4%) | 490 (81.9%) | < 0.001 |
Hydroxychloroquine | 49 (45.4%) | 409 (68.4%) | < 0.001 |
Tocilizumab | 17 (15.7%) | 34 (5.7%) | < 0.001 |
Remdesivir | 2 (1.9%) | 3 (0.5%) | 0.81 |
Convalescent plasma | 9 (8.3%) | 7 (1.2%) | < 0.001 |
Renal replacement therapy | 6 (5.6%) | 24 (4.0%) | 0.46 |
Vasopressors | 26 (24.1%) | 59 (9.9%) | < 0.001 |
ECMOa | 0 (0.0%) | 2 (0.3%) | 0.55 |
Clinical outcomes | |||
Length of stay (days) | 9 (5–14) | 7 (5–12) | 0.09 |
ICU admissiona | 29 (26.9%) | 112 (18.7%) | 0.05 |
Intubation | 27 (25.0%) | 91 (15.2%) | 0.01 |
Inpatient mortality | 32 (29.6%) | 120 (20.1%) | 0.03 |
14-day mortalityb | 21 (19.4%) | 102 (17.1%) | 0.60 |
30-day mortalityb | 37 (34.3%) | 145 (24.6%) | 0.04 |
30-day readmissionb | |||
Readmitted | 7/76 (9.2%) | 65/478 (13.6%) | 0.053 |
Not readmitted | 69/76 (90.8%) | 387/478 (81.0%) | |
Unknown | 0/76 (0.0%) | 26/478 (5.4%) | |
Disposition statusc | |||
Home | – | 363 (75.8%) | – |
Other facilities | – | 96 (20.0%) | |
Hospice home | – | 20 (4.2%) | |